In another phase 1 study, Teliso-V is being evaluated as monotherapy and in combination with osimertinib or erlotinib or nivolumab in previously treated c-Met-OE/EGFR mutant metastatic NSCLC [71]. The gene discussed is MET; the disease is non-small cell lung carcinoma.